DynamiCure Logo.png
DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced Cancers
08 nov. 2022 11h11 HE | DynamiCure Biotechnology, LLC
The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in...
Compass Therapeutics to Present at Upcoming Investment Conferences
08 nov. 2022 08h00 HE | Compass Therapeutics
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
08 nov. 2022 07h00 HE | Arvinas Inc.
– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling multiple clinical trials and initiating enrollment...
Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
07 nov. 2022 16h05 HE | Akoya Biosciences, Inc.
Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers Simplifies biomarker assay development and...
Affimed Logo.jpg
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
07 nov. 2022 08h05 HE | Affimed N.V.
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a...
Surface Logo_rgb[3].jpg
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
07 nov. 2022 08h00 HE | Surface Oncology, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Affimed Logo.jpg
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
03 nov. 2022 09h05 HE | Affimed N.V.
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an...
Compass Therapeutics Announces $80 Million Private Placement
02 nov. 2022 09h06 HE | Compass Therapeutics
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to...
Surface Logo_rgb[3].jpg
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
02 nov. 2022 06h30 HE | Surface Oncology, Inc.
– Two confirmed partial responses to SRF388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year –– Company focusing...
Arvinas to Present at Upcoming Conferences
01 nov. 2022 16h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...